Takara saw the highest growth of 1.99% in patent filings in June and 0.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Takara’s patent filings and grants. Buy the databook here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Takara has been focused on protecting inventions in United States(US) with five publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 33% filings and 80% grants. The United States(US), European Patent Office(EPO), World Intellectual Property Organization(WIPO), and Japan(JP) patent Office are among the top ten patent offices where Takara is filings its patents. Among the top granted patent authorities, Takara has 80% of its grants in United States(US) and 20% in Japan(JP).
Thermo Fisher Scientific and Roche could be the strongest competitors for Takara
Patents related to cell & gene therapy and cybersecurity lead Takara's portfolio
Takara has the highest number of patents in cell & gene therapy followed by, cybersecurity. For cell & gene therapy no patents were filed and 50% of patents were granted in Q2 2024.
Laboratory equipment related patents lead Takara portfolio followed by security services, and endpoint security
Takara has highest number of patents in laboratory equipment followed by security services, endpoint security, identity & access management.
For comprehensive analysis of Takara's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

